BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) (FWB: FME):
1st Quarter 2011 Summary:
| Net revenue | $3,036 million | +5% | ||||||
| Operating income (EBIT) | $445 million | +5% | ||||||
|
Net income attributable to Fresenius Medical Care AG & Co. KGaA |
$221 million |
+5% |
||||||
| Earnings per share | $0.73 | +4% | ||||||
Fresenius Medical Care AG & Co. KGaA (“the company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, today announced its results for the first quarter of 2011.
Revenue
Net revenue for the first quarter of 2011 increased by 5% to $3,036 million (+5% at constant currency) compared to the first quarter of 2010. Organic revenue growth worldwide was 3%. Dialysis services revenue grew by 5% to $2,285 million (+5% at constant currency) and dialysis product revenue increased by 6% to $751 million (+5% at constant currency).
North America revenue increased by 1% to $1,977 million including the impact of the new Medicare end-stage renal disease prospective payment system in the United States. Organic revenue growth was 1%. Dialysis services revenue grew by 1% to $1,782 million with a same market growth of 4%. Average revenue per treatment for U.S. clinics decreased to $348 in the first quarter of 2011 compared to $355 for the corresponding quarter in 2010 reflecting the targeted implementation of the new prospective payment system. Dialysis product revenue decreased by 2% to $195 million mainly due to lower pricing of renal drugs, partially offset by higher sales of dialysis products.
International revenue increased by 14% to $1,055 million. Based on constant currency, revenue grew by 13%. Organic revenue growth was 6%. Dialysis services revenue was $503 million, an increase of 23% (+21% at constant currency). Dialysis product revenue increased by 8% to $552 million and increased by 6% at constant currency, mainly driven by higher sales of peritoneal dialysis products, dialyzers, bloodlines, and products for acute care treatments.
Earnings
Operating income (EBIT) for the first quarter of 2011 increased by 5% to $445 million compared to $425 million in the first quarter of 2010. This resulted in an operating margin of 14.7% for the first quarter of 2011 compared to 14.8% for the corresponding quarter in 2010.
In North America, the operating margin increased from 15.7% to 15.8%. The margin development was mainly influenced by the favorable development of pharmaceutical costs and the negative effects of the implementation of the new Medicare end-stage renal disease prospective payment system in the United States.
In the International segment, the operating margin decreased from 16.4% to 16.2%.
Net interest expense for the first quarter of 2011 was $72 million, compared to $67 million in the first quarter of 2010. This development was mainly attributable to a higher debt level.
Income tax expense was $124 million for the first quarter of 2011 compared to $128 million in the first quarter of 2010 and reflecting effective tax rates of 33.3% and 35.6%, respectively.
Net income attributable to FMC AG & Co. KGaA for the first quarter of 2011 was $221 million, an increase of 5%, compared to the corresponding quarter of 2010.
Earnings per share (EPS) for the first quarter of 2011 rose by 4% to $0.73 per ordinary share compared to $0.70 for the first quarter of 2010. The weighted average number of shares outstanding for the first quarter of 2011 was approximately 302.3 million shares, compared to 299.6 million shares for the first quarter of 2010. The increase in shares outstanding resulted from stock option exercises in the past 12 months.
Cash flow
In the first quarter of 2011, the company generated $175 million in cash from operations, representing approximately 6% of revenue. The cash flow generation was supported by increased earnings and negatively influenced by an unfavorable development of DSOs, primarily related to the introduction of the new Medicare end-stage renal disease prospective payment system in the United States and raised inventory levels.
A total of $113 million was spent for capital expenditures, net of disposals. Free cash flow before acquisitions was $62 million compared to $250 million in the first quarter of 2010. A total of $339 million in cash was spent for acquisitions and investments, net of divestitures. Approximately $300 million of the expenditures was a minority investment in Renal Advantage Partners LLC, the parent company of Renal Advantage, Inc. Additionally, we have entered into agreements to provide renal products, pharmaceutical supplies and other services to Renal Advantage and Liberty Dialysis Inc.
Free cash flow after acquisitions, investments and divestitures was -$277 million, compared to $168 million in the first quarter of 2010.
Please refer to the attachments for a complete overview on the first quarter of 2011 and the reconciliation of non-GAAP financial measures included in this release to the most comparable GAAP financial measures.
Patients – Clinics – Treatments
As of March 31, 2011, Fresenius Medical Care treated 216,942 patients worldwide, which represents a 9% increase compared to the previous year’s figure. North America provided dialysis treatments for 138,392 patients, an increase of 4%. Including 21 clinics managed by Fresenius Medical Care North America, the number of patients in North America was 139,887. The International segment served 78,550 patients, an increase of 20% over the prior year’s figure.
As of March 31, 2011, the company operated a total of 2,769 clinics worldwide, which represents an 8% increase compared to the previous year’s figure. The number of clinics is comprised of 1,823 clinics in North America (1,844 including managed clinics), and 946 clinics in the International segment, representing an increase of 3% and 19%, respectively.
During the first quarter of 2011, Fresenius Medical Care delivered approximately 8.17 million dialysis treatments worldwide. This represents an increase of 9%, compared to last year’s figure. North America accounted for 5.24 million treatments, an increase of 4%. The International segment delivered 2.93 million treatments, an increase of 19%.
Employees
As of March 31, 2011, Fresenius Medical Care had 74,844 employees (full-time equivalents) worldwide, compared to 73,452 employees at the end of 2010. This increase of more than 1,300 employees is due to overall growth in the company’s business and acquisitions.
Debt/EBITDA ratio
The ratio of debt to Earnings before interest, taxes, depreciation and amortization (EBITDA) increased from 2.30 at the end of the first quarter of 2010 to 2.55 at the end of the first quarter of 2011. The debt/EBITDA ratio at the end of 2010 was 2.38.
Rating
Standard & Poor’s Ratings Services continues to rate the company’s corporate credit as ‘BB’ with a ‘positive’ outlook. Moody's continues to rate the company’s corporate credit as ‘Ba1’ with a ‘stable’ outlook, and Fitch continues to rate the company’s corporate credit as ‘BB’ with a ‘positive’ outlook. For further information on Fresenius Medical Care’s credit ratings, maturity profiles and credit instruments, please visit our website at www.fmc-ag.com / Investor Relations / Credit Relations.
Issuance of senior notes
In February 2011 Fresenius Medical Care issued $-denominated and €-denominated senior unsecured notes due 2021 in the respective principal amounts of $650 million and €300 million. The coupon for the $ senior notes is 5.75%, while the coupon for the € senior notes is 5.25%. The net proceeds amounted to approximately $1,035 million.
Acquisition of dialysis service business from Euromedic
On Jan. 4, 2011, Fresenius Medical Care announced the signing of a purchase agreement to acquire International Dialysis Centers (IDC), Euromedic’s dialysis service business for a purchase price of €485 million. Fresenius Medical Care is thus expanding its activities in the dialysis care market, especially in Eastern Europe, where IDC treats over 8,200 hemodialysis patients. The transaction remains subject to necessary regulatory approvals by the relevant anti-trust authorities and is expected to close in the second quarter of 2011. Upon completion, the acquired operations will add approximately $180 million in annual revenue and are expected to be accretive to earnings in the first year after closing of the transaction.
Outlook for 2011 raised
Based on the strong financial results in the first quarter of 2011 and the elimination of the so-called “transition adjustment” imposed on dialysis facilities (as part of the new Medicare end-stage renal disease prospective payment system) in the United States, the company raises its outlook for the full year 2011.
Revenue is now expected to grow to above $13 billion. Previously, the company expected revenue between $12.8 billion and $13.0 billion.
Net income attributable to FMC AG & Co. KGaA is now expected between $1.070 billion and $1.090 billion. Previously, the company expected net income between $1.035 billion and $1.055 billion.
For 2011, the company still expects to spend around 5% of revenue on capital expenditures and approximately $1.2 billion on acquisitions. The debt/EBITDA ratio is expected to be below or equal to 2.8 by the end of 2011, likewise unchanged from the previous guidance.
“We are pleased to report a successful first quarter of 2011 with strong operational performance – despite the expected implementation challenges posed by the new Medicare end-stage renal disease prospective payment system in the United States,” said Ben Lipps, chief executive officer of Fresenius Medical Care. “We would again like to express our appreciation to the Centers for Medicare & Medicaid Services (CMS) and the Administration for making this correction, and for their willingness in the past years to work with the entire kidney care community in the process of establishing the new reimbursement system, helping to improve the quality of life of all dialysis patient covered by Medicare.”
Conference call
Fresenius Medical Care will hold a conference call to discuss the results of the first quarter of 2011 on Wednesday, May 4, 2011, at 3:30 p.m. CEDT / 9:30 a.m. EDT. The company invites investors to view the live webcast of the call at the company’s website www.fmc-ag.com in the “Investor Relations” section. A replay will be available shortly after the call.
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,769 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 216,942 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
| Fresenius Medical Care | Three months ended | |||||
| Statement of Earnings | March 31, | |||||
| in US$ thousands, except share data | 2011 | 2010 | Change | |||
| unaudited | ||||||
| Net revenue | ||||||
| Dialysis care | 2,285,316 | 2,170,784 | 5.3% | |||
| Dialysis products | 751,072 | 711,345 | 5.6% | |||
| Total net revenue | 3,036,388 | 2,882,129 | 5.4% | |||
| Cost of revenue | 2,001,289 | 1,917,837 | 4.4% | |||
| Gross profit | 1,035,099 | 964,292 | 7.3% | |||
| Selling, general and administrative | 571,448 | 517,737 | 10.4% | |||
| Research and development | 26,149 | 23,089 | 13.3% | |||
| Income from equity method investees | (7,582) | (1,713) | 342.6% | |||
| Operating income (EBIT) | 445,084 | 425,179 | 4.7% | |||
| Interest income | (10,421) | (5,839) | 78.5% | |||
| Interest expense | 81,986 | 73,264 | 11.9% | |||
| Interest expense, net | 71,565 | 67,425 | 6.1% | |||
| Income before taxes | 373,519 | 357,754 | 4.4% | |||
| Income tax expense | 124,404 | 127,528 | -2.4% | |||
| Net income | 249,115 | 230,226 | 8.2% | |||
| Less: Net income attributable to noncontrolling interest | 28,414 | 19,110 | 48.7% | |||
| Net income attributable to FMC AG & Co. KGaA | 220,701 | 211,116 | 4.5% | |||
| Operating income (EBIT) | 445,084 | 425,179 | 4.7% | |||
| Depreciation and amortization | 135,984 | 124,458 | 9.3% | |||
| EBITDA | 581,068 | 549,637 | 5.7% | |||
| Total bad debt expenses | 52,685 | 60,271 | ||||
| Earnings per ordinary share | $0.73 | $0.70 | 3.6% | |||
| Earnings per ordinary ADS | $0.73 | $0.70 | 3.6% | |||
| Weighted average number of shares | ||||||
| Ordinary shares | 298,292,972 | 295,746,635 | ||||
| Preference shares | 3,957,435 | 3,889,994 | ||||
| In percent of revenue | ||||||
| Cost of revenue | 65.9% | 66.5% | ||||
| Gross profit | 34.1% | 33.5% | ||||
| Selling, general and administrative | 18.8% | 18.0% | ||||
| Research and development | 0.9% | 0.8% | ||||
| Income from equity method investees | -0.2% | -0.1% | ||||
| Operating income (EBIT) | 14.7% | 14.8% | ||||
| Interest expense, net | 2.4% | 2.3% | ||||
| Income before taxes | 12.3% | 12.4% | ||||
| Income tax expense | 4.1% | 4.4% | ||||
| Net income attributable to noncontrolling interest | 0.9% | 0.7% | ||||
| Net income attributable to FMC AG & Co. KGaA | 7.3% | 7.3% | ||||
| EBITDA | 19.1% | 19.1% | ||||
| Fresenius Medical Care | Three months ended | |||||
| Segment and Other Information | March 31, | |||||
| in US$ millions, unaudited | 2011 | 2010 | Change | |||
| Net revenue | ||||||
| North America | 1,977 | 1,960 | 0.9% | |||
| International | 1,055 | 922 | 14.4% | |||
| Corporate | 4 | - | 1,676.2% | |||
| Total net revenue | 3,036 | 2,882 | 5.4% | |||
| Operating income (EBIT) | ||||||
| North America | 312 | 308 | 1.4% | |||
| International | 171 | 151 | 13.3% | |||
| Corporate | (38) | (34) | 13.0% | |||
| Total operating income (EBIT) | 445 | 425 | 4.7% | |||
| Operating income in percent of revenue | ||||||
| North America | 15.8% | 15.7% | ||||
| International | 16.2% | 16.4% | ||||
| Total | 14.7% | 14.8% | ||||
| Employees | ||||||
| Full-time equivalents | 74,844 | 69,329 | ||||
| Fresenius Medical Care | ||||
| Reconciliation of non U.S. GAAP | ||||
| financial measures to the most directly | Three months ended | |||
| comparable U.S. GAAP financial measures | March 31, | |||
| in US$ millions, unaudited | 2011 | 2010 | ||
| Segment information North America | ||||
| Net revenue | 1,977 | 1,960 | ||
| Costs of revenue and research and development | 1,315 | 1,327 | ||
| Selling, general and administrative | 358 | 327 | ||
| Income from equity method investees | (8) | (2) | ||
| Costs of revenue and operating expenses | 1,665 | 1,652 | ||
| Operating income (EBIT) | 312 | 308 | ||
| In percent of revenue | 15.8% | 15.7% | ||
| Dialysis products revenue incl. and excl. internal sales | ||||
| North America | ||||
| Dialysis products revenue incl. internal sales | 377 | 366 | ||
| less internal sales | (182) | (166) | ||
| Dialysis products external sales | 195 | 200 | ||
| International | ||||
| Dialysis products revenue incl. internal sales | 644 | 591 | ||
| less internal sales | (92) | (80) | ||
| Dialysis products external sales | 552 | 511 | ||
| Reconciliation of cash flow from operating activities to EBITDA 1) | ||||
| Total EBITDA | 581 | 550 | ||
| Interest expense, net | (72) | (67) | ||
| Income tax expense | (124) | (128) | ||
| Change in working capital and other non-cash items | (210) | (6) | ||
| Net cash provided by operating activities | 175 | 349 | ||
| Annualized EBITDA | ||||
| Operating income (EBIT) last twelve months | 1,944 | 1,785 | ||
| Depreciation and amortization last twelve months | 514 | 476 | ||
| Non-cash charges | 47 | 51 | ||
| Annualized EBITDA | 2,505 | 2,312 | ||
|
1) EBITDA is the basis for determining compliance with
certain covenants in Fresenius Medical
Care's long-term debt instruments. |
||||
| Fresenius Medical Care | March 31, | December 31, | ||
| Balance Sheet | (unaudited) | (audited) | ||
| in US$ millions | 2011 | 2010 | ||
| Assets | ||||
| Current assets | 5,715 | 5,153 | ||
| Intangible assets | 8,902 | 8,833 | ||
| Other non-current assets | 3,497 | 3,109 | ||
| Total assets | 18,114 | 17,095 | ||
| Liabilities and equity | ||||
| Current liabilities | 3,469 | 3,790 | ||
| Long-term liabilities | 6,478 | 5,501 | ||
| Noncontrolling interest subject to put provisions | 291 | 280 | ||
| Total equity | 7,876 | 7,524 | ||
| Total liabilities and equity | 18,114 | 17,095 | ||
| Equity/assets ratio: | 43% | 44% | ||
| Debt | ||||
| Short-term borrowings | 132 | 671 | ||
| Short-term borrowings from related parties | 36 | 10 | ||
| Current portion of long-term debt and capital lease obligations | 265 | 264 | ||
| Trust preferred securities | 651 | 625 | ||
| Long-term debt and capital lease obligations, less current portion | 5,313 | 4,310 | ||
| Total debt | 6,397 | 5,880 | ||
| Fresenius Medical Care | ||||
| Cash Flow Statement | ||||
| Three months ended March 31, | 2011 | 2010 | ||
| in US$ millions, unaudited | ||||
| Operating activities | ||||
| Net income | 249 | 230 | ||
| Depreciation / amortization | 136 | 125 | ||
| Change in working capital and other non-cash items | (210) | (6) | ||
| Cash flow from operating activities | 175 | 349 | ||
| Investing activities | ||||
| Purchases of property, plant and equipment | (117) | (106) | ||
| Proceeds from sale of property, plant and equipment | 4 | 7 | ||
| Capital expenditures, net | (113) | (99) | ||
| Free cash flow | 62 | 250 | ||
|
Acquisitions and investments, net of cash acquired and purchases of intangible assets |
(339) | (84) | ||
| Proceeds from divestitures | - | 2 | ||
| Acquisitions and investments, net of divestitures | (339) | (82) | ||
| Free cash flow after investing activities | (277) | 168 | ||
| Financing activities | ||||
| Change in accounts receivable securitization program | (510) | (214) | ||
| Change in intercompany debt | 24 | - | ||
| Change in other debt | 862 | 21 | ||
| Proceeds from exercise of stock options | 2 | 17 | ||
| Distributions to noncontrolling interest | (25) | (34) | ||
| Contributions from noncontrolling interest | 4 | 8 | ||
| Cash flow from financing activities | 357 | (202) | ||
| Effect of exchange rates on cash | 17 | (3) | ||
| Net increase (decrease) in cash | 97 | (37) | ||
| Cash at beginning of period | 523 | 301 | ||
| Cash at end of period | 620 | 264 | ||
| Fresenius Medical Care | ||||||||||
| Quarterly Performance Scorecard - Revenue | ||||||||||
| Three months ended March 31, | 2011 | cc | 2010 | cc | ||||||
|
in US$ thousands, except per-treatment revenue, |
||||||||||
|
unaudited |
||||||||||
| North America | ||||||||||
| Net revenue | 1,977,288 | 1,959,689 | ||||||||
| Growth year-over-year | 0.9% | 10.5% | ||||||||
| Dialysis care | 1,782,001 | 1,760,389 | ||||||||
| Growth year-over-year | 1.2% | 11.6% | ||||||||
| U.S. per treatment | 348 | 355 | ||||||||
| Per treatment | 340 | 348 | ||||||||
| Sequential growth | -1.9% | -0.6% | ||||||||
| Growth year-over-year | -2.2% | 5.0% | ||||||||
| Dialysis products | ||||||||||
| Incl. internal sales | 376,716 | 365,416 | ||||||||
| Growth year-over-year | 3.1% | 6.0% | ||||||||
| External sales | 195,287 | 199,299 | ||||||||
| Growth year-over-year | -2.0% | 1.3% | ||||||||
| International | ||||||||||
| Net revenue | 1,055,233 | 922,223 | ||||||||
| Growth year-over-year | 14.4% | 13.0% | 17.4% | 7.6% | ||||||
| Dialysis care | 503,315 | 410,395 | ||||||||
| Growth year-over-year | 22.6% | 21.2% | 18.5% | 8.9% | ||||||
| Per treatment | 172 | 170 | 166 | 152 | ||||||
| Sequential growth | 1.7% | -4.3% | ||||||||
| Growth year-over-year | 3.4% | 2.2% | 10.0% | 1.1% | ||||||
| Dialysis products | ||||||||||
| Incl. internal sales | 643,954 | 591,306 | ||||||||
| Growth year-over-year | 8.9% | 7.6% | 17.6% | 7.4% | ||||||
| External sales | 551,917 | 511,828 | ||||||||
| Growth year-over-year | 7.8% | 6.4% | 16.4% | 6.7% | ||||||
| cc = at constant exchange rates | ||||||||||
| Fresenius Medical Care | ||||
| Quarterly Performance Scorecard - Dialysis care volume | ||||
| Three months ended March 31, unaudited | 2011 | 2010 | ||
| North America | ||||
| Number of treatments | 5,241,652 | 5,034,516 | ||
| Treatments per day | 68,073 | 65,383 | ||
| Per day sequential growth | 0.6% | 2.2% | ||
| Per day year-over-year growth | 4.1% | 4.7% | ||
| Same market growth year-over-year | 3.7% | 4.1% | ||
| International | ||||
| Number of treatments | 2,933,190 | 2,474,048 | ||
| Same market growth year-over-year | 5.6% | 4.3% | ||
| Fresenius Medical Care | ||||
| Quarterly Performance Scorecard - Expenses | ||||
| Three months ended March 31, unaudited | 2011 | 2010 | ||
| North America | ||||
| Costs of revenue and operating expenses | ||||
| In percent of revenue | 84.2% | 84.3% | ||
| Selling, general and administrative | ||||
| In percent of revenue | 18.1% | 16.7% | ||
| Bad debt expenses | ||||
| In percent of revenue | 2.6% | 2.9% | ||
| Dialysis care operating expenses/treatment (in US$) | 282 | 289 | ||
| Sequential growth | 0.4% | 2.6% | ||
| Growth year-over-year | -2.5% | 2.5% | ||
| Total Group | ||||
| Costs of revenue and operating expenses | ||||
| In percent of revenue | 85.3% | 85.2% | ||
| Selling, general and administrative | ||||
| In percent of revenue | 18.8% | 18.0% | ||
| Effective tax rate | 33.3% | 35.6% | ||
| Fresenius Medical Care | ||||
| Quarterly Performance Scorecard - Cash Flow/Investing Activities | ||||
| Three months ended March 31, | 2011 | 2010 | ||
| in US$ thousands, except number of de novos, unaudited | ||||
| Total Group | ||||
| Operating cash flow | 175,319 | 349,088 | ||
| In percent of revenue | 5.8% | 12.1% | ||
| Free cash flow before acquisitions | 62,159 | 250,047 | ||
| In percent of revenue | 2.0% | 8.7% | ||
| Acquisitions and investments, net of divestitures | 338,792 | 81,578 | ||
| Capital expenditures, net | 113,160 | 99,041 | ||
| In percent of revenue | 3.7% | 3.4% | ||
| Maintenance | 77,056 | 56,985 | ||
| In percent of revenue | 2.5% | 2.0% | ||
| Growth | 36,104 | 42,056 | ||
| In percent of revenue | 1.2% | 1.5% | ||
| Number of de novos | 22 | 17 | ||
| North America | 15 | 7 | ||
| International | 7 | 10 | ||
| Fresenius Medical Care | ||||
| Quarterly Performance Scorecard - Balance Sheet | ||||
| March 31, unaudited | 2011 | 2010 | ||
| Total Group | ||||
| Debt (in US$ millions) | 6,397 | 5,310 | ||
| Debt/EBITDA | 2.6 | 2.3 | ||
| North America | ||||
| Days sales outstanding | 60 | 52 | ||
| International | ||||
| Days sales outstanding | 116 | 111 | ||
| Fresenius Medical Care | ||||||||||
| Quarterly Performance Scorecard | ||||||||||
| Three months ended March 31, | 2011 | 2010 | ||||||||
| North America (U.S.) | ||||||||||
| Clinical Performance | ||||||||||
| Single Pool Kt/v > 1.2 | 97% | 96% | ||||||||
| Hemoglobin = 10-12 g/dl | 73% | 65% | ||||||||
| Hemoglobin = 10-13 g/dl | 88% | 87% | ||||||||
| Calcium = 8.4-10.2 mg/dl | 79% | 80% | ||||||||
| Albumin >= 3.5 g/dl 1) | 84% | 83% | ||||||||
| No catheter | 76% | 73% | ||||||||
| Phosphate <= 5.5mg/dl | 63% | 60% | ||||||||
|
Hospitalization Days per patient
(12 months ending March 31) |
9.8 | 9.9 | ||||||||
| Demographics | ||||||||||
| Average age (in years) | 62 | 62 | ||||||||
| Average time on dialysis (in years) | 3.7 | 3.6 | ||||||||
| Average body weight (in kg) | 81 | 81 | ||||||||
| Prevalence of diabetes | 56% | 55% | ||||||||
| Europe, Middle East and Africa | ||||||||||
| Clinical Performance | ||||||||||
| Single Pool Kt/v > 1.2 | 96% | 95% | ||||||||
| Hemoglobin = 10-12 g/dl | 54% | 52% | ||||||||
| Hemoglobin = 10-13 g/dl | 77% | 77% | ||||||||
| Calcium = 8.4-10.2 mg/dl | 77% | 79% | ||||||||
| Albumin >= 3.5 g/dl 1) | 89% | 87% | ||||||||
| No catheter | 82% | 81% | ||||||||
| Phosphate <= 5.5mg/dl | 76% | 77% | ||||||||
|
Hospitalization Days per patient
(12 months ending March 31) |
9.8 | 8.9 | ||||||||
| Demographics | ||||||||||
| Average age (in years) | 64 | 64 | ||||||||
| Average time on dialysis (in years) | 4.9 | 4.8 | ||||||||
| Average body weight (in kg) | 71 | 70 | ||||||||
| Prevalence of diabetes | 28% | 28% | ||||||||
| 1) International standard BCR CRM470 | ||||||||||